文献速递细菌感染、耐药与抗菌药物

OPS-2071对革兰阳性和革兰阴性肠道致病菌的体外抗菌活性

In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究采用琼脂稀释法等方法,评估新型喹诺酮类抗生素OPS-2071对主要肠道致病菌的体外抗菌活性及耐药风险。结果显示OPS-2071对革兰阳性菌和空肠弯曲菌(包括喹诺酮耐药株)活性优于参考药物,对自发耐药的发生频率较低,提示其可能对包括喹诺酮耐药弯曲菌在内的肠道感染有用。

要点

  • OPS-2071对革兰阳性菌和空肠弯曲菌(含喹诺酮耐药株)的体外活性强于参考药物。
  • 对金黄色葡萄球菌和大肠埃希菌未观察到自发耐药,对空肠弯曲菌的自发耐药低于现有喹诺酮类。
  • OPS-2071对金黄色葡萄球菌和空肠弯曲菌的突变预防浓度低于受试化合物。

核心结论

  • OPS-2071广谱且强效的体外抗菌活性及较低的耐药风险提示其可能对包括喹诺酮耐药弯曲菌在内的主要病原体所致肠道感染有用。

研究设计与样本

  • 采用琼脂稀释法评估OPS-2071的抗菌活性;通过超螺旋分析和解链分析分别测定对DNA旋转酶和拓扑异构酶IV的抑制活性;通过在含药琼脂上接种测定突变预防浓度和自发耐药频率。

主要发现

  • 与参考药物相比,OPS-2071对革兰阳性菌和空肠弯曲菌(包括喹诺酮耐药株)的抗菌活性更强。
  • 对 other 革兰阴性菌,OPS-2071与现有喹诺酮类活性相当。
  • 对携带喹诺酮耐药突变的DNA旋转酶的抑制活性与抗菌活性密切相关。
  • 在金黄色葡萄球菌和大肠埃希菌中未观察到对OPS-2071的自发耐药;在空肠弯曲菌中,OPS-2071的自发耐药低于现有喹诺酮类、高于阿奇霉素。
  • OPS-2071对金黄色葡萄球菌和空肠弯曲菌的突变预防浓度低于受试化合物,对大肠埃希菌的突变预防浓度略高于现有喹诺酮类。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enteric infections are a major public health issue in developing countries. Antimicrobial resistance is also a problem for enteric infection. OPS-2071 is a novel quinolone antibiotic with low oral absorption and potent antibacterial activity against Clostridioides difficile. OBJECTIVES: This study was conducted to confirm the antimicrobial activity of OPS-2071 against major enteropathogenic bacteria and to evaluate the risk of emergence of drug resistance. METHODS: The antibacterial activity was evaluated by the agar dilution method. The inhibitory activity against DNA gyrase and topoisomerase IV was determined by supercoiling assay and decatenation assay, respectively. The mutant prevention concentration and frequency of spontaneous resistance were determined by inoculation on drug-containing agar. RESULTS: Compared with the reference drugs, the antibacterial activity of OPS-2071 was more potent against Gram-positive bacteria and Campylobacter jejuni, including quinolone-resistant strains. Against other Gram-negative bacteria, OPS-2071 was comparable to existing quinolones. The inhibitory activities against DNA gyrase with quinolone-resistant mutations closely correlated with the antibacterial activity. Spontaneous resistance to OPS-2071 was not observed in Staphylococcus aureus and Escherichia coli and was lower than that of existing quinolones and higher than that of azithromycin in C. jejuni. The mutant prevention concentration of OPS-2071 was lower than that of tested compounds in S. aureus and C. jejuni and slightly higher than that of existing quinolones in E. coli. CONCLUSIONS: The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Oka D, Changkwanyeun R, Yamaguchi T, et al. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria. J Antimicrob Chemother. 2022. PMID: 36101508. doi:10.1093/jac/dkac308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。